Flying Publisher, 2011. - 113 р.
This Guide will discuss the available strategies for those whointerrupt, fail or relapse after treatment, in particular
the benefits and risks of current therapeutic options
the categories of patients with therapeutic failure that
should be re-treated
the appropriate measures for therapy monitoring and
outcomes assessment
As a growing number of non-responders and relapsers are seen in clinical practice there is a permanent search for new antiviral, anticellular and immunomodulator drugs. Year 2011 has brought the approval of the first generation of viral protease inhibitors
that will offer higher cure rates for non-responders and open the door for the eventual testing of interferon-free regimens.Antiviral Therapy: The Basics
Antiviral therapy – Standard of Care (SoC)
Predictors of response before treatment
Virus factors
Host factors
Co-morbidities
Treatment related factors
Adverse effects associated with therapy
Response-guided therapy (RGT)
Nonresponders and relapsers
Outlook
Links
Patients’ monitoring during and after treatment
Basic knowledge
Viral kinetics: methodology
Viral load monitoring
Real-time PCR tests
HCV genotyping
Assessment of hepatic fibrosis
Liver biopsy
Non invasive methods
Correlation between biochemical, histological and
virological markers and HCV treatment
Outlook
Links
Antiviral therapy in non-responders, relapsers and special
populations.
How to manage genotype 1 non-responders and relapsers ?
Therapy selection: monitoring vs. retreatment
|
Therapeutical strategies
Practical approach to retreatment
How to manage genotype 2 and 3 non-responders and
relapsers ?
Nonresponders/relapsers infected with HCV G2/
Retreatment of HCV genotype 2 and 3 patients
Special categories of patients
Injecting drug users (IDUs)
Hemodialysis patients
Patients with psychiatric comorbidities
Patients with inherited anemias
African Americans
HIV-HCV coinfection
Outlook
Links
Searching for new antiviral therapies
Candidates for new therapeutic approaches
New IFN formulations
Alternative RBV formulation
Direct-Acting Antivirals (DAAs)
Protease inhibitors (PIs)
Triple therapy
Other investigational HCV PIs
HCV polymerase inhibitors
NS5A inhibitors
Host cyclophilins inhibitors
Emergence of drug resistant mutations
What does the future hold?
Outlook
Links
Management of recurrent HCV infection following liver transplantation
Natural history of recurrent HCV infection after liver
transplantation
Prophylactic antiviral therapy in cirrhosis
Pre-emptive antiviral therapy after LT
Therapy of recurrent hepatitis C after LT
Side effects and safety of PegIFN/RBV therapy
Retransplantation for recurrent HCV cirrhosis
Outlook
Links
References
Appendix – Selected drug profiles
Pegasys™
PegIntron™
Infergen™
Ribavirin
Incivek™ (Telaprevir)
Victrelis™ (Boceprevir)
